Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

Lucia Del Mastro,Mauro Mansutti,Giancarlo Bisagni,Riccardo Ponzone,Antonio Durando,Laura Amaducci,Alessandra Fabi,Antonio Frassoldati,Andrea Michelotti,Antonio Pazzola,E Valle,G. Sanna,Stefania Gori,Sabino De Placido,Ornella Garrone,Michela Donadio,Paolo Bruzzi,Claudia Bighin,Matteo Lambertini,Francesca Poggio

Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

2019

504Background: The effect of extended adjuvant endocrine therapy (ET) with aromatase inhibitors(AI) after sequential ET with tamoxifen(Tam) followed by AI for 5 years is still controversial. We c...

Keywords:

Endocrine system
Physical therapy
Letrozole
Internal medicine
Oncology
Adjuvant therapy
Medicine
Adjuvant
Aromatase
endocrine therapy
Pathology
Tamoxifen

Correction
Source
Cite
Save

References

Citations